ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

obudanersen

Also written as “ION582”.

Its studies are mostly in Angelman Syndrome, led by Ionis Pharmaceuticals.

Drug pageObudanersen: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 22, 20253 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ionis Pharmaceuticals33 open or runningphase 3since Mar 22, 2025Nov 9, 2021Aug 2027phase 3 · NCT06914609

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2021First study: phase 2 study in Angelman SyndromeFirst studyNCT05127226 · 71 enrolled · United States, Australia, France and more
  2. Feb 13, 2025Named obudanersenINNProposed as its International Nonproprietary Name in WHO's List 132 · before, ION582
  3. Mar 22, 2025Phase 3 study in Angelman SyndromeNCT06914609 · 156 enrolled · United States, Australia, Canada and more
  4. Aug 20, 2026Phase 3 study in Angelman SyndromeNCT07782827 · 30 planned · United States
  5. Nov 17, 2026Primary completion moved from 2029-03 to 2032-03Date moved laterphase 2 · +36 months · NCT05127226

Ahead

  1. Aug 2027Primary completion: phase 3 study in Angelman SyndromeNCT06914609
  2. May 2028Primary completion: phase 3 study in Angelman SyndromeNCT07782827
  3. Mar 2032Primary completion: phase 2 study in Angelman SyndromeNCT05127226

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07782827Angelman Syndrome · United States3RecruitingMay 202830
NCT06914609Angelman Syndrome · United States, Australia, Canada and more3Active, not recruitingAug 2027156
NCT05127226Angelman Syndrome · United States, Australia, France and more2Active, not recruitingMar 203271

How it is read

Names in the registry

  • “obudanersen”, 2 entries
  • “ION582”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.